Recombinant Human Periostin/OSF-2 (C60A) His-tag Protein, CF

Recombinant Human Periostin/OSF‑2 (C60A) His-tag Protein (Catalog # 11486-F2) supports the adhesion of ATDC5 mouse chondrogenic cells. The ED50 for this effect is 0.500‑6.00 μg/mL.

2 μg/lane of Recombinant Human Periostin/OSF‑2 (C60A) His-tag Protein (Catalog # 11486-F2) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 68-90 kDa, under reducing conditions.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Periostin/OSF-2 (C60A) His-tag Protein, CF Summary

• Details of Functionality: Measured by its ability to induce adhesion of ATDC5 mouse chondrogenic cells. The ED₅₀ for this effect is 0.500-6.00 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human Periostin/OSF-2 protein
  Asn22-Gln808 (C60A) with a C-terminal 6-His tag
• Accession #: Q15063.1
• N-terminal Sequence: Asn22
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 89 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 68-90 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Periostin/OSF-2 (C60A) His-tag Protein, CF

• Fasciclin I-like
• MGC119510
• MGC119511
• OSF2
• OSF-2
• OSF-2osteoblast specific factor 2 (fasciclin I-like)
• OSF2periodontal ligament-specific periostin
• Osteoblast-specific factor 2
• PDLPOSTN
• periostin isoform thy2
• periostin isoform thy4
• periostin isoform thy6
• periostin isoform thy8
• Periostin
• periostin, osteoblast specific factor
• PNRP11-412K4.1
• POSTN
• TRIF52

Background

Periostin, also known as OSF-2, is a secreted matricellular protein with functions in extracellular matrix formation, cell migration, and inflammation (1). It is secreted as a 90 kDa monomer that can aggregate into >170 kDa higher-order multimers (2). Periostin contains an N-terminal EMI domain followed by four tandem FAS1 domains (3). Mature human Periostin shares 91% amino acid sequence identity with mouse and rat Periostin. Alternative splicing generates additional isoforms with various deletions in the C-terminal region following the FAS domains. Periostin is expressed by mesenchymal cells such as vascular smooth muscle cells, fibroblasts, osteoblasts, and odontoblasts in developing teeth (4-7). Periostin binds to Integrins alpha v beta 3 and alpha v beta 5 (2, 9), leading to enhanced cell adhesion and cell migration (2, 5, 6). It enhances Fibronectin and Collagen I production and promotes collagen fibrillogenesis (10, 11). Periostin is also up-regulated in many carcinomas (2, 8) and induces epithelial-mesenchymal transition, tumor growth, invasion, and metastasis (9). Further, Periostin induces the expression of VEGF R2 on endothelial cells and VEGF-C in tumor cells, and it can induce tumor lymphangiogenesis (8, 12). Periostin plays an important role in heart valve development and tissue healing after myocardial infarction (5, 13, 14). In asthma, it is up-regulated in bronchial epithelium and plays both destructive and protective roles by inducing eosinophil infiltration and inhibiting goblet cell metaplasia and mucus production, respectively (15, 16).

1. Liu, A.Y. et al. (2014) Matrix Biol. 37:150.
2. Gillan, L. et al. (2002) Cancer Res. 62:5358.
3. Takeshita, S. et al. (1993) Biochem. J. 294:271.
4. Kruzynska-Frejtag, A. et al. (2004) Dev. Dyn. 229:857.
5. Lindner, V. et al. (2005) Arterioscler. Thromb. Vasc. Biol. 25:77.
6. Horiuchi, K. et al. (1999) J. Bone Miner. Res. 14:1239.
7. Li, G. et al. (2006) Atherosclerosis 188:292.
8. Shao, R. et al. (2004) Mol. Cell. Biol. 24:3992.
9. Yan, W. and R. Shao (2006) J. Biol. Chem. 281:19700.
10. Erkan, M. et al. (2007) Gastroenterology 132:1447.
11. Norris, R.A. et al. (2007) J. Cell. Biochem. 101:695.
12. Kudo, Y. et al. (2012) PLoS One 7:e44488.
13. Snider, P. et al. (2008) Circ. Res. 102:752.
14. Kuhn, B. et al. (2007) Nat. Med. 13:962.
15. Blanchard, C. et al. (2008) Mucosal Immunol. 1:289.
16. Sehra, S. et al. (2011) J. Immunol. 186:4959.

Bioinformatics

• Uniprot:
  • Q15063.1()